La catena delle opzioni mostra i dati chiave delle opzioni azionarie di HeartBeam a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per HeartBeam..

HeartBeam (NASDAQ:BEAT) Azioni, Catena delle Opzioni

HeartBeam

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

HeartBeam Inc

News

Offerings

BEAT

Heartbeam Filed For Common Stock Offering Of Up To $10M

WIIM

Heartbeam shares are trading lower amid a possible selloff. The stock initially traded higher after the company announced FDA clearance for its HeartBeam system, but it has since reversed.

General

HeartBeam shares are trading higher after the FDA granted the company 510(k) clearance of its system for comprehensive arrhythmia assessment.

HeartBeam Announced FDA Clearance For Its HeartBeam System For Comprehensive Arrhythmia Assessment

Biotech

HeartBeam Unveils Data At AHA 2024 For Portable Credit Card-Sized ECG Device; Studies Demonstrate Comparable Arrhythmia Detection To Standard ECGs And Highlight Remote Chest Pain Evaluation To Reduce Heart Attack Care Delays

Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) with a Speculative Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent.

Earnings

Earnings Misses

HeartBeam Q3 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

Management

HeartBeam Appoints Robert Eno As CEO To Lead U.S. Commercialization Efforts, While Founder Branislav Vajdic Transitions To President To Focus On Advancing Vector-Based Technology And AI Applications For Heart Health

HeartBeam Appoints Timothy Cruickshank As Chief Financial Officer, Effective Immediately

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year.

HeartBeam Q2 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54089132&amp;newsitemid=20240701576961&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=a8e16bb73468ac62714a82d6f6ae9bb7">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap&#xAE; Index effective after the market close on June 28, 2024 as part of FTSE Russell's annual reconstitution.

HeartBeam Added To Russell Microcap Index

New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company's AI Program
Data Show That Applying AI to VCG Data Provides More Consistent and Reliable Detection of Atrial Flutter

HeartBeam's Study Demonstrates AI Algorithm Combined with Vectorcardiography Outperforms Panel Of Cardiologists in Detecting Arrhythmias

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 66 percent increase over losses of $(0.50) per share from the same period last year.

HeartBeam Q1 2024 GAAP EPS $(0.17) Misses $(0.15) Estimate

<h3>Gainers</h3>
<ul>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares moved upwards by 7.17% to $1.06. The company's market cap stands at $3.8 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) shares moved upwards by 6.72% to $0.2. The market value of their outstanding shares is at $10.7 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares rose 5.85% to $0.77. The company's market cap stands at $5.2 million. </li>
<li>Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) shares increased by 5.43% to $0.25. The company's market cap stands at $69.1 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock rose 5.24% to $0.91. The market value of their outstanding shares is at $2.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) shares declined by 16.4% to $0.12 during Friday's after-market session. The company's market cap stands at $3.5 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) stock decreased by 10.36% to $1.98. The company's market cap stands at $52.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares decreased by 6.71% to $0.3. The market value of their outstanding shares is at $3.0 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 5.04% to $7.35. The company's market cap stands at $6.2 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares fell 5.0% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 5.0% to $0.69. The company's market cap stands at $12.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AFIB

ALZN

APVO

ASXC

GRTX

MBIO

MNPR

NBSE

PALI

TRVN

YCBD

12 Health Care Stocks Moving In Friday's After-Market Session

New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company's Deep Learning Technology
Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables

HeartBeam Presents Results On AI Capabilities For Detecting Arrhythmias

Shares of FedEx Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fdx#NYSE">FDX</a>) rose sharply in today&rsquo;s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion <a href="https://www.benzinga.com/news/earnings/24/03/37881578/fedex-stock-climbs-on-q3-results-eps-beat-5b-share-buyback">share repurchase program</a>.
FedEx reported quarterly earnings of $3.86 per share which beat the analyst consensus estimate of $3.45 by 11.88% and represents a 13.2% increase over earnings of $3.41 per share from the same period last year. Quarterly sales came in at $21.7 billion, missing the analyst consensus estimate of $22.04 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
FedEx shares surged 12.4% to $297.72 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Murano Global Investments PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) shares rose 266.4% to $35.43 in pre-market trading after falling 46% on Thursday.</li>
<li>Nova LifeStyle, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvfy#NASDAQ">NVFY</a>) rose 62.5% to $2.99 in pre-market trading after gaining around 22% on Thursday.</li>
<li>BIOLASE, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biol#NASDAQ">BIOL</a>) shares rose 32.8% to $0.1990 in pre-market trading after the company reported better-than-expected fourth-quarter earnings results.</li>
<li>Griid Infrastructure Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grdi#NASDAQ">GRDI</a>) climbed 30.9% to $1.44 in pre-market trading.</li>
<li>Visionary Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gv#NASDAQ">GV</a>) shares gained 16.1% to $0.1950 in pre-market trading after dipping 6% on Thursday.</li>
<li>SU Group Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sugp#NASDAQ">SUGP</a>) gained 13.1% to $3.29 in pre-market trading after declining around 9% on Thursday.</li>
<li>HeartBeam, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beat#NASDAQ">BEAT</a>) shares rose 10.8% to $2.56 in pre-market trading as the company reported fourth-quarter financial results.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) gained 9% to $1.46 in pre-market trading after gaining 8% on Thursday. Ocugen recently appointed Huma Qamar, MD, MPH as Chief Medical Officer.</li>
<li>Worthington Steel, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ws#NYSE">WS</a>) gained 3.9% to $33.15 in pre-market trading as the company posted stronger-than-expected results for its third quarter on Thursday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) dipped 17.6% to $0.6398 in pre-market trading after declining over 6% on Thursday.</li>
<li>Lululemon Athletica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) declined 12.8% to $417.25 in pre-market trading. Lululemon posted better-than-expected results for its fourth quarter, but issued a weak forecast for the first quarter.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) fell 11.5% to $0.2478 pre-market trading after jumping around 30% on Thursday.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) fell 11.3% to $4.40 in pre-market trading after falling over 8% on Thursday. The company, on Thursday, reported FY23 financial results.</li>
<li>Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) fell 11.3% to $7.20 pre-market trading after dipping 15% on Thursday.</li>
<li>Asset Entities Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asst#NASDAQ">ASST</a>) fell 10.9% to $0.5750 in pre-market trading. Asset Entities shares surged around 23% on Thursday after the company announced that it entered into an agreement with Zendrop.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares tumbled 10.7% to $2.05 in pre-market trading after gaining 20% on Thursday.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) shares fell 9.1% to $0.14 in pre-market trading after surging 14% on Thursday.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares fell 8.4% to $0.0461 in pre-market trading after dipping 16% on Thursday.</li>
<li>NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares tumbled 6.3% to $94.49. Nike reported upbeat earnings and sales results for its third quarter on Thursday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37885620/fedex-nike-and-3-stocks-to-watch-heading-into-friday"> FedEx, Nike And 3 Stocks To Watch Heading Into Friday</a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

ABTS

ASST

BIOL

EGOX

GRDI

ISPR

JOAN

LULU

MRNO

NVFY

OCGN

PYXS

SLNA

SUGP

Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
HeartBeam missed estimated earnings by 0.0%, reporting an EPS of $-0.13 versus an estimate of $-0.13.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 10.0% drop in the share price the next day.

To track all earnings releases for HeartBeam <a href="https://www.benzinga.com/quote/BEAT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: HeartBeam Q4 Earnings

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
HeartBeam (NASDAQ:<a href="https://investorplace.com/stock-quotes/beat-stock-quote/">BEAT</a>) just reported results for the second quarter of 2024.<ul><li>HeartBeam reported earnings per share of -19 cents. This was below the analyst estimate for EPS of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/beat-stock-earnings-heartbeam-for-q2-of-2024/">BEAT Stock Earnings: HeartBeam Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BEAT Stock Earnings: HeartBeam Misses EPS for Q2 2024

HeartBeam names Cruickshank as finance chief

The latest announcement is out from HeartBeam ( ($BEAT) ). HeartBeam, Inc. has strengthened its executive team by appointing Timothy Cruickshank as...

HeartBeam Appoints New CFO to Bolster Financial Strategy

HeartBeam appoints Robert Eno as CEO

Heartbeam, Inc. ( ($BEAT) ) has released its Q3 earnings. Here is a breakdown of the information Heartbeam, Inc. presented to its investors. HeartB...

HeartBeam, Inc. Advances Cardiac Monitoring Solutions

HeartBeam GAAP EPS of -$0.19

HeartBeam, Inc. (BEAT) Q3 2024 Earnings Call Transcript

HeartBeam rises on positive data from two studies on its vector-based technology

HeartBeam (BEAT) announced the results from two studies evaluating HeartBeam's groundbreaking vector-based technology. The data add to the body of ...

HeartBeam announces positive data from two studies at AHA

HeartBeam (BEAT) announced that the US Food and Drug Administration FDA has granted 510(k) clearance of the HeartBeam system for comprehensive arrh...

HeartBeam announces FDA clearance for high-fidelity ECG system

BEATW

Press Releases

HeartBeam Names Timothy Cruickshank as Chief Financial Officer

HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist

HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

Lifesaving Portable, AI Augmented Cardiac Monitoring Technology Poised for Commercial Launch Under New Industry Leader CEO: Heartbeam, Inc. (NASDAQ: BEAT)

HeartBeam Named "Rising Star" at the 6th Annual Digital Health Hub Foundation Awards

HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time

HeartBeam Reports Third Quarter 2024 Results

HeartBeam Announces Positive Data from Two Studies at Prestigious American Heart Association Conference

HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

HeartBeam to Attend JP Morgan 2025 Annual Healthcare Conference

Apyx Medical

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

HeartBeam

HeartBeam (BEAT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO